Translational and Transformational

Clinical studies have been conducted in over 3000 patients, published in over 50 conference proceedings and five medical articles in high-impact peer-reviewed rheumatology journals, describing the clinical applications of 14-3-3η. Available as a diagnostic test, the first of the biomarker portfolio, the 14-3-3η protein assay is Health Canada approved as an IVD offered by Dynacare and provided as a laboratory-developed test in the United States through Quest Diagnostics, LabCorp and RDL.

Collaboration-Driven
The key to Augurex’s successful advancement of 14-3-3η programs has been collaborations with top-tier international scientific and clinical researchers. Our guiding principle is to work with experts in their respective areas along the continuum of studies from design to data analysis and publication to address important clinical unmet needs in well-characterized cohorts.

Biomarker-Evidence Based
Conducting basic science and clinical research in a previously unstudied area requires a commitment to evidence-based and open-minded evaluation of new, and potentially unexpected findings, to direct the continued research path.

Augurex is transforming health management through
biologically-informed, integrated digital solutions.

What we believe

People are taking unprecedented control of their health and disease management. Innovative technology that connects patients to their clinicians and various credible information sources is allowing individuals to take control of their own health. Through a combination of remote and in-person expert clinician oversight people can successfully take a preventative approach to their health while ensuring their best outcomes in clinical care.

The life sciences industry is undergoing a data-driven transformation. With rapid technology advancements, utilization of data and the breadth of its applications in the healthcare system we will reach unprecedented coordination of care for people preventing and fighting disease.

Data integration and exchange between expert clinicians and patients is critical: the whole is greater than the sum of the connected parts for optimal healthcare.

Doing our part

Augurex has a responsibility to bring its innovations closer to the patient.

We are enabling near-patient clinical decisions through point-of-care proprietary blood testing that connects with disease specific applications and electronic health records. Robust, connected, rapid point-of-care testing provides immediate, actionable results at each juncture where clinical decisions should be made.

Integrating results through digital applications will streamline care and improve outcomes.

How it works

Starting with rheumatoid arthritis we work with worldwide opinion leaders to solve early diagnosis and referral problems.

Across autoimmune and chronic conditions our near-patient tests and digital health solutions enable tight disease control to reduce the social and economic burden of disease.

We keep people healthy with predictive biomarkers and best-in-class integrated solutions. Digital applications are transforming the ability to empower patients to participate actively in their own care, with a greater focus on well-being, to prevent disease, to predict the most appropriate treatment and to personalise the management of long-term conditions such as rheumatoid arthritis.

Augurex Life Sciences Corp. news

Contact supplier